This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.40, marking a +1.09% move from the previous day.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
Pfizer (PFE) Stock Moves -1.78%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $45.17, moving -1.78% from the previous trading session.
AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November
Dow 30 Stock Roundup: BA's $383M Modification Contract, MSFT's Army Contract
by Swarup Gupta
The Dow recovered from two weeks of losses to post strong gains this week.
Pfizer (PFE) Up 4.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche (RHHBY) to Acquire Jecure and Enter the NASH Space
by Zacks Equity Research
Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $44.90 in the latest trading session, marking a +1.88% move from the prior day.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity
by Zacks Equity Research
Pfizer (PFE) receives pediatric exclusivity for its epilepsy drug, Lyrica, extending the exclusivity period to Jun 30, 2019.
Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
by Zacks Equity Research
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.
Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.
The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer
Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
by Zacks Equity Research
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod
by Swarup Gupta
The Dow traversed a particularly difficult holiday-shortened week.
Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days
by Zacks Equity Research
Pfizer (PFE) wins an FDA nod for Daurismo in combination with low-dose cytarabine regarding newly-diagnosed AML in adults. This is the fourth cancer drug approval on the trot in less than 90 days.
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
by Zacks Equity Research
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Corcept Initiates Phase III Study for Cushing's Syndrome
by Zacks Equity Research
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails
by Zacks Equity Research
Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $44.20, moving +1.57% from the previous trading session.